{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:37:10Z","timestamp":1761561430702},"reference-count":88,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.bbapap.2010.04.009","type":"journal-article","created":{"date-parts":[[2010,4,26]],"date-time":"2010-04-26T08:46:43Z","timestamp":1272271603000},"page":"1974-1987","source":"Crossref","is-referenced-by-count":13,"title":["Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: A comparative proteomic approach"],"prefix":"10.1016","volume":"1804","author":[{"given":"Irene","family":"Colavita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Catanzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junia V.","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Ruoppolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbapap.2010.04.009_bib1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbapap.2010.04.009_bib2","doi-asserted-by":"crossref","first-page":"8652","DOI":"10.1038\/sj.onc.1206194","article-title":"BCR\/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations","volume":"21","author":"Pane","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.bbapap.2010.04.009_bib3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/asheducation-2003.1.132","article-title":"Chronic myeloid leukemia","volume":"1","author":"Melo","year":"2003","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.bbapap.2010.04.009_bib4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.hoc.2004.03.008","article-title":"Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation","volume":"18","author":"Melo","year":"2004","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.bbapap.2010.04.009_bib5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbapap.2010.04.009_bib6","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbapap.2010.04.009_bib7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/10428190801896103","article-title":"Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib","volume":"49","author":"Hantschel","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbapap.2010.04.009_bib8","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbapap.2010.04.009_bib9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbapap.2010.04.009_bib10","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbapap.2010.04.009_bib11","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbapap.2010.04.009_bib12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2006.07.010","article-title":"Resistance to imatinib mesylate in chronic myeloid leukaemia","volume":"249","author":"Melo","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbapap.2010.04.009_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-1-15","article-title":"P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia","volume":"1","author":"Cang","year":"2008","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbapap.2010.04.009_bib14","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1182\/blood.V94.7.2200.419a33_2200_2207","article-title":"BCR\/ABL mRNA and the P210(BCR\/ABL) protein are down-modulated by interferon-alpha in chronic myeloid leukemia patients","volume":"94","author":"Pane","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbapap.2010.04.009_bib15","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.bbapap.2010.04.009_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCRABL for the treatment of imatinib resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbapap.2010.04.009_bib17","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbapap.2010.04.009_bib18","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2methylpyrimidinylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbapap.2010.04.009_bib19","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo Activity of SKI-606, a novel Src-Abl inhibitor, against imatinib resistant Bcr-Abl+neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2010.04.009_bib20","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbapap.2010.04.009_bib21","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant BCR_ABL mutation-negative leukemia and persistent activation of lyn kinase","volume":"100","author":"Wu","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbapap.2010.04.009_bib22","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.biocel.2007.10.001","article-title":"Overcoming kinase resistance in chronic myeloid leukemia","volume":"40","author":"Lee","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bbapap.2010.04.009_bib23","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/sj.leu.2401429","article-title":"Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth","volume":"13","author":"Roginskaya","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.bbapap.2010.04.009_bib24","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and Lyn kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbapap.2010.04.009_bib25","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-03-1484","article-title":"Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia","volume":"64","author":"Donato","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2010.04.009_bib26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.bbapap.2010.04.009_bib27","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbapap.2010.04.009_bib28","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1021\/pr0603708","article-title":"Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance","volume":"6","author":"Ferrari","year":"2007","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbapap.2010.04.009_bib29","first-page":"121","article-title":"Cytogenetic characterisation and proteomic profiling of the Imatinib-resistant cell line KCL22-R","volume":"31","author":"Rosenhahn","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbapap.2010.04.009_bib30","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1021\/pr0704128","article-title":"Comparative proteome profiling and functional analysis of chronic myelogenous leukemia cell lines","volume":"6","author":"Fontana","year":"2007","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbapap.2010.04.009_bib31","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1042\/BST0351347","article-title":"Characterization of cancer stem cells in chronic myeloid leukaemia","volume":"35","author":"J\u00f8rgensen","year":"2007","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bbapap.2010.04.009_bib32","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.bcp.2005.02.021","article-title":"Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR\/ABL-positive cell lines","volume":"69","author":"Miyoshi","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbapap.2010.04.009_bib33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1634\/stemcells.21-3-315","article-title":"Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22\/SR","volume":"21","author":"Ohmine","year":"2003","journal-title":"Stem Cells"},{"key":"10.1016\/j.bbapap.2010.04.009_bib34","doi-asserted-by":"crossref","first-page":"725","DOI":"10.5483\/BMBRep.2005.38.6.725","article-title":"Identification of differentially expressed proteins in imatinib mesylate-resistant chronic myelogenous cells","volume":"38","author":"Park","year":"2005","journal-title":"J. Biochem. Mol. Biol."},{"key":"10.1016\/j.bbapap.2010.04.009_bib35","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.bbrc.2005.08.201","article-title":"Differential tyrosine phosphorylation of leukemic cells during apoptosis as a results of treatment with imatinib mesylate","volume":"336","author":"Park","year":"2005","journal-title":"Biochem. Biophys. Res. Comm."},{"key":"10.1016\/j.bbapap.2010.04.009_bib36","doi-asserted-by":"crossref","first-page":"6316","DOI":"10.1074\/jbc.M410598200","article-title":"Global effects of BCR\/ABL and TEL\/PDGFR\u03b2 expression on the proteome and phosphoproteome","volume":"280","author":"Unwin","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2010.04.009_bib37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jim.2005.07.012","article-title":"Evaluation of CML model cell lines and imatinib mesylate response: determinants of signaling profiles","volume":"305","author":"Wetzel","year":"2005","journal-title":"J. Immunol. Meth."},{"key":"10.1016\/j.bbapap.2010.04.009_bib38","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1002\/pmic.200800298","article-title":"Difference gel electrophoresis","volume":"8","author":"Timms","year":"2008","journal-title":"Proteomics"},{"key":"10.1016\/j.bbapap.2010.04.009_bib39","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1080\/10253890701314863","article-title":"Tumor necrosis factor-associated protein 1 (TRAP-1) protects cells from oxidative stress and apoptosis","volume":"10","author":"Montesano Gesualdi","year":"2007","journal-title":"Stress"},{"key":"10.1016\/j.bbapap.2010.04.009_bib40","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1002\/pmic.200701035","article-title":"Proteomic analysis of an imatinib-resistant K562 cell line highlights opposing roles of heat shock cognate 70 and heat shock 70 proteins in resistance","volume":"8","author":"Pocaly","year":"2008","journal-title":"Proteomics"},{"key":"10.1016\/j.bbapap.2010.04.009_bib41","doi-asserted-by":"crossref","first-page":"21878","DOI":"10.1074\/jbc.M605018200","article-title":"Antagonism or synergism. Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signalling","volume":"281","author":"Wang","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2010.04.009_bib42","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and non kinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbapap.2010.04.009_bib43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6807-9-7","article-title":"The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)","volume":"9","author":"Winger","year":"2009","journal-title":"BMC Struct. Biol."},{"key":"10.1016\/j.bbapap.2010.04.009_bib44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/jbiol134","article-title":"Exploiting the promiscuity of imatinib","volume":"8","author":"Lee","year":"2009","journal-title":"J. Biol."},{"key":"10.1016\/j.bbapap.2010.04.009_bib45","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jprot.2008.08.002","article-title":"Proteomic analysis of the porcine platelet proteome and alterations induced by thrombin activation","volume":"71","author":"Esteso","year":"2008","journal-title":"Proteomics"},{"key":"10.1016\/j.bbapap.2010.04.009_bib46","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbapap.2010.04.009_bib47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0014-5793(86)80657-3","article-title":"Malic enzyme levels are increases by the activation of NADPH-consuming pathways: detoxification processes","volume":"202","author":"Ayala","year":"1986","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbapap.2010.04.009_bib48","first-page":"821","article-title":"High activities of NADP+-dependent isocitrate dehydrogenase and malic enzyme in rabbit lens epithelial cells","volume":"29","author":"Winkler","year":"1988","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.bbapap.2010.04.009_bib49","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0301-472X(03)00265-0","article-title":"Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate","volume":"31","author":"Tipping","year":"2003","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bbapap.2010.04.009_bib50","doi-asserted-by":"crossref","first-page":"7414","DOI":"10.1073\/pnas.0900653106","article-title":"Charting the molecular network of the drug target Bcr-Abl","volume":"106","author":"Brehme","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbapap.2010.04.009_bib51","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.bcp.2006.04.029","article-title":"NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs","volume":"72","author":"Celli","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbapap.2010.04.009_bib52","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nchembio.216","article-title":"Target profiling of small molecules by chemical proteomics","volume":"5","author":"Rix","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbapap.2010.04.009_bib53","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","article-title":"Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells","volume":"23","author":"Remsing","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bbapap.2010.04.009_bib54","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1089\/ars.2008.2071","article-title":"Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications","volume":"10","author":"Rodrigues","year":"2008","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.bbapap.2010.04.009_bib55","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.exphem.2004.01.007","article-title":"Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line","volume":"32","author":"Tarumoto","year":"2004","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bbapap.2010.04.009_bib56","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00003088-200544040-00002","article-title":"Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism","volume":"44","author":"Rochat","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbapap.2010.04.009_bib57","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0006-291X(02)00947-6","article-title":"Redox regulation of pro-inflammatory cytokines and IkappaB-alpha\/NF-kappaB nuclear translocation and activation","volume":"296","author":"Haddad","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbapap.2010.04.009_bib58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11010-007-9639-7","article-title":"Decreased glutathione levels potentiate the apoptotic efficacy of selenium: possible involvement of p38 and JNK MAPKs in vitro","volume":"309","author":"Ranawat","year":"2008","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bbapap.2010.04.009_bib59","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0083-6729(07)00005-2","article-title":"Quinone oxidoreductases and vitamin K metabolism","volume":"78","author":"Gong","year":"2008","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.bbapap.2010.04.009_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2005.09.019","article-title":"NRH:quinone reductase 2: an enzyme of surprises and mysteries","volume":"71","author":"Vella","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbapap.2010.04.009_bib61","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","article-title":"Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors","volume":"25","author":"Bantscheff","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbapap.2010.04.009_bib62","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1038\/sj.onc.1206406","article-title":"Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways","volume":"22","author":"Matsuda","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bbapap.2010.04.009_bib63","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-03-1484","article-title":"Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia","volume":"64","author":"Donato","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2010.04.009_bib64","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1152\/physrev.2001.81.2.807","article-title":"Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation","volume":"81","author":"Kyriakis","year":"2001","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bbapap.2010.04.009_bib65","doi-asserted-by":"crossref","first-page":"49460","DOI":"10.1074\/jbc.M406059200","article-title":"Interactions between extracellular signal-regulated protein kinase 1, 14-3-3 and heat shock factor 1 during stress","volume":"279","author":"Wang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2010.04.009_bib66","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1349-7006.2009.01365.x","article-title":"Contribution of BCR-ABL-independent activation of ERK1\/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells","volume":"101","author":"Nambu","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbapap.2010.04.009_bib67","first-page":"355","article-title":"The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome","volume":"11","author":"An","year":"2000","journal-title":"Cell Growth Differ."},{"key":"10.1016\/j.bbapap.2010.04.009_bib68","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/sj.onc.1202525","article-title":"Oncogenic potential of Hsp72","volume":"18","author":"Volloch","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.bbapap.2010.04.009_bib69","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/sj.leu.2401841","article-title":"Heat shock proteins\u2014modulators of apoptosis in tumour cells","volume":"14","author":"Creagh","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.bbapap.2010.04.009_bib70","doi-asserted-by":"crossref","first-page":"9041","DOI":"10.1038\/sj.onc.1207114","article-title":"Heat-shock proteins as regulators of apoptosis","volume":"22","author":"Takayama","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bbapap.2010.04.009_bib71","first-page":"5761","article-title":"Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin","volume":"62","author":"Nimmanapalli","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbapap.2010.04.009_bib72","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1182\/blood-2004-05-2041","article-title":"Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells","volume":"105","author":"Guo","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbapap.2010.04.009_bib73","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.leu.2404463","article-title":"Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia","volume":"21","author":"Pocaly","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbapap.2010.04.009_bib74","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood-2005-03-037648","article-title":"Hypusination of eukaryotic initiation factor 5A(eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach","volume":"109","author":"Balabanov","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbapap.2010.04.009_bib75","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0002-9440(10)62535-7","article-title":"Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas\/leukemias: combination analysis with cDNA expression array and tissue microarray","volume":"159","author":"Oka","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbapap.2010.04.009_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(03)00400-1","article-title":"The function of the protein tyrosine phosphatase SHP-1 in cancer","volume":"306","author":"Wu","year":"2003","journal-title":"Gene"},{"key":"10.1016\/j.bbapap.2010.04.009_bib77","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/path.2178","article-title":"Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia","volume":"212","author":"Amin","year":"2007","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbapap.2010.04.009_bib78","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/onc.2009.7","article-title":"Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients","volume":"28","author":"Samanta","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.bbapap.2010.04.009_bib79","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2006-04-019141","article-title":"SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl","volume":"109","author":"Chen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbapap.2010.04.009_bib80","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.bbrc.2003.12.117","article-title":"Annexin-I expression modulates drug resistance in tumor cells","volume":"314","author":"Wang","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbapap.2010.04.009_bib81","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1046\/j.1432-1327.2000.01345.x","article-title":"Annexin I is a stress protein induced by heat, oxidative stress and a sulfhydrylreactive agent","volume":"267","author":"Rhee","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bbapap.2010.04.009_bib82","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0014-4827(03)00310-0","article-title":"Annexin 1 regulates cell proliferation by disruption of cell morphology and inhibition of cyclin D1 expression through sustained activation of the ERK1\/2 MAPK signal","volume":"290","author":"Alldridge","year":"2003","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bbapap.2010.04.009_bib83","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0002-9440(10)63098-2","article-title":"Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status","volume":"164","author":"Garcia Pedrero","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbapap.2010.04.009_bib84","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0014-5793(03)00570-2","article-title":"Annexin A1 processing is associated with caspase-dependent apoptosis in BZR cells","volume":"546","author":"Debret","year":"2003","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbapap.2010.04.009_bib85","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/sj.bjp.0704054","article-title":"Transfection of annexin 1 in monocytic cells produces a high degree of spontaneous and stimulated apoptosis associated with caspase-3 activation","volume":"133","author":"Solito","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbapap.2010.04.009_bib86","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1096\/fj.02-0941fje","article-title":"A novel calcium dependent proapoptotic effect of annexin 1 on human neutrophils","volume":"17","author":"Solito","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.bbapap.2010.04.009_bib87","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1242\/jcs.115.8.1591","article-title":"Human CAP1 is a key factor in the recycling of cofilin and actin for rapid actin turnover","volume":"115","author":"Moriyama","year":"2002","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bbapap.2010.04.009_bib88","doi-asserted-by":"crossref","first-page":"18985","DOI":"10.1074\/jbc.M910297199","article-title":"Individual subunits of the eukaryotic cytosolic chaperonin mediate interactions with binding sites located on subdomains of b-actin","volume":"275","author":"Hynes","year":"2000","journal-title":"J. Biol. Chem."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S157096391000107X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S157096391000107X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T18:51:25Z","timestamp":1635274285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S157096391000107X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":88,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S157096391000107X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbapap.2010.04.009","relation":{},"ISSN":["1570-9639"],"issn-type":[{"value":"1570-9639","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}